Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIVEC with Gemcitabine for NMIBC
NCT06327932Phase 3Not yet recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Apr 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of gemcitabine in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Cancer Center of Guangzhou Medical University. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
gemcitabine
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06327932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06327932.